晨间唾液可的松筛查肾上腺功能不全的诊断准确性研究
该回顾性横断面诊断准确性研究纳入2017至2024年间在英国单中心接受ACTH兴奋试验的449名疑似肾上腺功能不全患者,共517次试验,确诊104次(20.1%)。基线唾液可的松预测肾上腺功能不全的AUC为0.93,与血清皮质醇相当(0.93,p=0.67),优于唾液皮质醇(0.87,p=0.00063)。研究确定了排除阈值≥703 ng/dL(19.5 nmol/L)和纳入阈值<180 ng/dL(5.0 nmol/L),以及中间阈值<389 ng/dL(10.8 nmol/L)用于指导临床决策。
要点
- 晨间唾液可的松筛查肾上腺功能不全的准确性不劣于血清皮质醇。
- 排除阈值≥19.5 nmol/L,纳入阈值<5.0 nmol/L,中间阈值<10.8 nmol/L。
- 唾液可的松为居家无创筛查提供新选择。
核心结论
- 基线晨间唾液可的松在筛查肾上腺功能不全方面表现至少与血清皮质醇相当。
研究设计与样本
- 回顾性横断面诊断准确性研究,2017至2024年英国单中心,纳入449名参与者共517次ACTH兴奋试验。
主要发现
- 104次试验(20.1%)确诊肾上腺功能不全。
- 基线唾液可的松AUC为0.93(95%CI 0.91-0.95),与血清皮质醇AUC 0.93(95%CI 0.90-0.95)无显著差异(p=0.67)。
- 唾液可的松AUC优于唾液皮质醇AUC 0.87(95%CI 0.82-0.91)(p=0.00063)。
- 排除阈值≥703 ng/dL(19.5 nmol/L)灵敏度0.97(95%CI 0.92-0.99),特异度0.59(95%CI 0.54-0.63)。
- 纳入阈值<180 ng/dL(5.0 nmol/L)灵敏度0.58(95%CI 0.48-0.67),特异度0.97(95%CI 0.95-0.98);中间阈值<389 ng/dL(10.8 nmol/L)灵敏度0.83(95%CI 0.74-0.89),特异度0.87(95%CI 0.83-0.90)。
关键数值与推荐
- 排除肾上腺功能不全的唾液可的松阈值:≥703 ng/dL(19.5 nmol/L)。
- 纳入肾上腺功能不全的唾液可的松阈值:<180 ng/dL(5.0 nmol/L)。
- 考虑糖皮质激素覆盖的中间阈值:<389 ng/dL(10.8 nmol/L)。
临床怎么用
- 晨间唾液可的松可用于疑似肾上腺功能不全的初筛,避免静脉穿刺和清晨就诊。
- 根据唾液可的松结果分层:≥19.5 nmol/L可排除,<5.0 nmol/L可纳入,<10.8 nmol/L可考虑经验性糖皮质激素覆盖并等待确诊试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Morning serum cortisol is used to screen for adrenal insufficiency, but requires venepuncture, early morning clinic attendance, and may be affected by altered corticosteroid-binding globulin (CBG) levels. Salivary cortisone is a non-invasive, home-based alternative. OBJECTIVE: To assess the diagnostic accuracy of morning salivary cortisone for screening adrenal insufficiency and establish clinically relevant thresholds. DESIGN: Retrospective cross-sectional diagnostic accuracy study (2017 to 2024). SETTING: Single tertiary oncology and endocrinology center in the United Kingdom. PARTICIPANTS: Consecutive patients undergoing adrenocorticotropin hormone (ACTH) stimulation test for suspected adrenal insufficiency. INTERVENTION: Salivary sampling for cortisone and cortisol. MAIN OUTCOME MEASURES: Sensitivity and specificity of baseline salivary cortisone. RESULTS: A total of 517 ACTH stimulation tests in 449 participants were included; adrenal insufficiency was confirmed in 104 tests (20.1%). Baseline salivary cortisone accurately predicted adrenal insufficiency (area under the receiver operating characteristic curve [AUC] 0.93, 95% CI [0.91-0.95]), similar to serum cortisol (0.93, 0.90-0.95; p = 0.67) and superior to salivary cortisol (0.87, 0.82-0.91; p = 0.00063). A baseline salivary cortisone rule-out threshold ≥703 ng/dL (19.5 nmol/L) (sensitivity 0.97 [95% CI 0.92-0.99]; specificity 0.59 [0.54-0.63]) and a rule-in threshold <180 ng/dL (5.0 nmol/L) (sensitivity 0.58 [0.48-0.67]; specificity 0.97 [0.95-0.98]) provided the highest net benefit. An intermediate threshold <389 ng/dL (10.8 nmol/L) (sensitivity 0.83 [0.74-0.89]; specificity 0.87 [0.83-0.90]) identified patients for whom glucocorticoid cover should be considered while awaiting confirmatory testing. CONCLUSION: Baseline morning salivary cortisone performs at least as well as serum cortisol for adrenal insufficiency screening.
引用
- Televantos C, Monaghan PJ, Michaelidou M, et al. Diagnostic Accuracy Study of Morning Salivary Cortisone for Screening Adrenal Insufficiency in a Real-World Cohort. J Clin Endocrinol Metab. 2026. PMID: 42806822. doi:10.1210/clinem/dgag401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。